Geron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
February 28, 2019 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market...
Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
January 31, 2019 16:20 ET
|
Geron Corporation
Aleksandra Rizo, M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical OfficerAdditional office to be opened in New Jersey to support expansion of...
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
December 03, 2018 16:22 ET
|
Geron Corporation
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --...
Geron to Host Analyst and Investor Event on December 10, 2018
November 28, 2018 17:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday,...
Geron to Present at Upcoming Investor Conferences in November
November 07, 2018 16:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present a...
Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
November 01, 2018 16:05 ET
|
Geron Corporation
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology...
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
November 01, 2018 07:00 ET
|
Constellation Pharmaceuticals , Inc.
- Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
November 01, 2018 06:20 ET
|
Geron Corporation
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron...
Geron to Announce Third Quarter 2018 Financial Results on November 1, 2018
October 25, 2018 06:00 ET
|
Geron Corporation
MENLO PARK, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2018 financial results after the market closes on...
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...